Trevi Therapeutics Completes $115 Million Offering to Fund Development of Chronic Cough Treatment Trevi Therapeutics has successfully closed a $115 million underwritten offering to support its chronic cough treatment initiatives, including Haduvio™.

Trevi Therapeutics Completes $115 Million Offering to Fund Development of Chronic Cough Treatment #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Nasdaq_TRVI

Trevi Therapeutics Secures $100 Million from Underwritten Stock Offering Trevi Therapeutics has successfully announced a $100 million public offering of common stock to support its investigational therapy Haduvio™.

Trevi Therapeutics Secures $100 Million from Underwritten Stock Offering #United_States #New_Haven #Trevi_Therapeutics #Haduvio #Nasdaq_TRVI